BC Platforms supports national pathway for cancer vaccine trials
BC Platforms co-developed the Cancer Vaccine Launch Pad’s central referral tool, supporting a national pathway to cancer vaccine clinical trials.
In a new article published in Applied Clinical Trials, Susanna Lövdahl, VP of Data Operations at BC Platforms, examines how life sciences companies can generate credible rare disease evidence when no registry or mature natural history dataset exists. The article explores why evidence strategy must be designed from the start with intended use, endpoints, harmonization, and data provenance defined early to meet the standards expected for drug development decisions and regulatory submissions.
For teams designing these studies, the principle is easy to state and harder to achieve: start from the evidentiary standard and work backwards. Define the population and endpoints before collecting data, set the rules for harmonization and provenance at the design stage, and keep quality control independent. Investing this effort upfront rarely slows a study down; in fact, it reduces rework and helps teams answer regulatory questions with confidence because the data-generating process is well understood and documented. The aim is not to eliminate uncertainty but to generate the most reliable evidence the situation allows, and to be transparent about its strengths and its limits.